De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine.
PMID: 27079793
2016
Annals of clinical microbiology and antimicrobials
Abstract: Specifically, we found one rtM204I+rtL180 M+rtM250 V+rtA181 V clone among 23 clones from patient 1 (4.35 %), one rtM204 V+vrtL180 M +rtM250 V+rtA181 V clone among 24 clones from patient 2 (4.17 %), and 2 clones harboring rtM204 V+rtL180 M+rtM250 V+rt
Higher detection rates of amino acid substitutions in HBV reverse transcriptase/surface protein overlapping sequence is correlated with lower serum HBV DNA and HBsAg levels in HBeAg-positive chronic hepatitis B patients with subgenotype B2.
PMID: 27006281
2016
Infection, genetics and evolution
Abstract: In addition, two patients harboring drug resistance mutations rtL80V+rtM204I and rtL180M+rtM204V were found.
Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy.
PMID: 26889227
2016
Experimental and therapeutic medicine
Abstract: Clonal analysis further revealed that the rtS202G or rtT184F was in all cases co-localized with rtL180M and rtM204V in any single virus isolate clone.
Abstract: In patient A, the rtL180M, rtS202G and rtM204V mutant variants were detected using pyrosequencing prior to virological breakthrough.
Abstract: In patient B, the rtL180M, rtM204I and
Prevalence of mutations in HBV DNA polymerase gene associated with nucleos(t)ide resistance in treatment-naive patients with Chronic Hepatitis B in Central China.
PMID: 26876337
2016
The Brazilian journal of infectious diseases
Abstract: Mutations in HBV DNA polymerase were detected in 24 patients (8.9%) including rtM204I/V (n=6), rtN236T (n=5), rtM250V (n=2), rtL180M (n=2), rtT184G (n=1), rtM207I (n=1), rtS202I (n=1), rtM204V/I & rtL180M (n=5), and rtM204I &
Dynamics of Genotypic Mutations of the Hepatitis B Virus Associated With Long-Term Entecavir Treatment Determined With Ultradeep Pyrosequencing: A Retrospective Observational Study.
Figure: (B) From 1 to 2 years, the resistant variants (rtL180 M, rtM204 V, rtS202G) began to rise to a high peak (84.60%, 79.56%, 76.88%), and double amino acid substitutions (rtL180M+rtM204 V) and triple substitutions (rtL180M+rtM204V+rtS202G) also began to rise.
Figure: A wave of resistant variants (rtM204 V [19.95%], rt
Broad Range of Hepatitis B Virus (HBV) Patterns, Dual Circulation of Quasi-Subgenotype A3 and HBV/E and Heterogeneous HBV Mutations in HIV-Positive Patients in Gabon.
Abstract: The mutation M204V/I conferring resistance to 3TC was more common in HBV/A (47.4%) than in HBV/E isolates (0%) (P = .04).
Result: Regarding RAMs, the mutation M204V/I, associated with the compensatory mutation L180M, was significantly more common in genotype HBV/A (9/19, 47.4%) than in genotype HBV/E (0/9, 0%) (Yate's corrected chi2, P = .04) (Fig 6,
Discussion: Importantly, we identified in our survey three natural M204V/I mutations in 3TC-naive patients, as already described in other settings.
Discussion: Third, the M204V/I RAM were more common in HBV/A strains.
Discussion: When considering HBV/A genotypes only, we observed a high (~50%) prevalence of M204V/I and L180M mutations.
Evaluation of the dynamic pattern of viral evolution in patients with virological breakthrough during treatment with nucleoside/nucleotide analogs by ultradeep pyrosequencing.
Result: In all four patients, the M204V mutation was accompanied by the L180M mutation, and an identical trend was observed in the two mutation sites (Table III).
Result: Notably, the mutation rate of rtM204I/V was markedly increased at the time of virological breakthrough in eight patients, and this was accompanied by an increased mutation rate of rtL180M and/or rtL80I/V.
Result: the M204V mutation in patients E and F eventually disappeared following the ADV add-on therapy, which also occurred in the other two patients.
Discussion: Additionally, the present study revealed that YVDD-variant-dominated virological bre
Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones.
Abstract: RESULTS: TDF susceptibilities of lamivudine-resistant clones (rtL180M/M204V) and lamivudine plus entecavir-resistant clones (rtL180M/S202G/M204V) were similar to wild type clones in vitro.
Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE).
PMID: 26136470
2016
The Journal of infectious diseases
Abstract: The most frequently encountered primary mutation was M204V/I (48.7%), followed by A181T/V (3.8%) and N236T (2.6%).
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.
Abstract: All patients had at least one ETV-resistance mutation: rtT184A/C/F/G/I/L/S (n=49), rtS202G (n=43) and rtM250L/V (n=7), in addition to rtM204V/I (n=90).
HBV mutation literature information.
PMID: 
2016
Annals of clinical microbiology and antimicrobials
Browser Board
Co-occurred Entities
Filtrator
ViMRT